Centene Director Files to Sell ~$197k in CNC Stock
CENTENE CORP
Subscribe to track CNC
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Centene Director Files to Sell ~$197k in CNC Stock
Company: Centene Corporation (CNC) Form: 144 | Filed: 2025-10-15 Significance: Low
Insider: Wayne S DeVeydt Title: Director | Relationship: Director
Transaction: • Type: Proposed Sale • Shares: 5,489 • Price: ~$35.84 • Value: $196,736.97 • Owned After: Not Disclosed
Key Insight: A director has filed a notice to sell shares worth approximately $197k. These shares were acquired as a stock bonus just two weeks prior, suggesting the sale may be for tax purposes or diversification.
Market Context: This is a relatively small transaction for a company director. The filing also notes a prior sale of over $300k in the last three months, indicating a pattern of selling.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: Centene Corporation (CNC)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A Director of Centene Corporation, Wayne S DeVeydt, has filed a Form 144 notice for the proposed sale of 5,489 shares of common stock, valued at approximately $197k. The shares were acquired as a stock bonus only two weeks prior to the proposed sale date.
- Market Impact: The impact on the market is expected to be neutral. The sale is of a small size and appears to be related to personal financial management (e.g., tax obligations from the bonus, diversification) rather than a change in outlook on the company's future.
Company Information
| Field | Value |
|---|---|
| Company | Centene Corporation |
| Ticker Symbol | CNC |
| CIK | 0001071739 |
| Industry | Hospital & Medical Service Plans |
Insider Information
| Field | Value |
|---|---|
| Name | Wayne S DeVeydt |
| CIK | 0001321392 |
| Title/Position | Director |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 (Notice of Proposed Sale) |
| Transaction Date | 2025-10-15 (Approximate Sale Date) |
| Transaction Code | Not Applicable |
| Security Type | Common Stock |
| Shares Involved | 5,489 |
| Price Per Share | ~$35.84 (Calculated) |
| Total Value | $196,736.97 |
| Shares Owned After | Not Disclosed |
| Ownership Type | Not Disclosed |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The total value of the proposed sale is relatively minor for an insider of a large-cap company like Centene. Sales of shares acquired via bonuses or option exercises are common for liquidity and tax planning and are not typically seen as a strong negative signal by the market unless the size is exceptionally large.
Volume & Sentiment
- Expected Volume Impact: Negligible. The transaction size is too small to significantly impact daily trading volume.
- Sentiment Indicator: Neutral. While insider selling is never bullish, the context of this transaction (selling a recent bonus) mitigates any bearish sentiment.
Investment Insights
Positive Market Indicators
- No direct positive indicators can be drawn from this notice of a proposed sale.
Risk Factors
- The filing notes a previous sale of 10,775 shares for $314,545.12 on September 9, 2025. This establishes a recent pattern of selling by the director, which could be a minor point of concern if it continues or accelerates.
Key Takeaways
- Routine Sale: The transaction appears to be a routine sale of shares received as compensation.
- Low Value: The monetary value of the sale is not significant enough to signal a major change in the insider's confidence in the company.
- Pattern of Selling: This is the second sale by this insider in as many months, a pattern worth monitoring for any future escalation.
Contextual Analysis
Timing Significance
The shares for this proposed sale were acquired as a 'Stock Bonus' on October 1, 2025. The plan to sell them on or around October 15, 2025, indicates a rapid monetization of the compensation, which is common for insiders to cover the income tax liability incurred upon vesting.
Transaction Context
Form 144 is a notice of intent to sell restricted or control securities. It does not mean the sale has occurred, but that it may occur within the next 90 days. The filing does not mention a 10b5-1 trading plan.
Company Context
This filing should be viewed in the broader context of Centene's recent performance, news, and upcoming earnings reports. Without that context, this individual filing holds minimal predictive power.
Risk Assessment
Risk Level: Low
Risk Factors
- Insider Selling Pattern: A continued pattern of selling from one or more insiders could signal a lack of confidence, though current activity is not at an alarming level.
- Source of Shares: Selling shares received as compensation is less concerning than selling shares that were purchased on the open market.
Market Considerations
- Sector Performance: The performance of the broader healthcare and managed care sector can influence stock performance more than a small insider sale.
- Company Fundamentals: Investors should focus on Centene's revenue, earnings, and growth prospects rather than this single transaction.
IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.
Analysis generated on 2025-10-15 | Data source: SEC EDGAR
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.